Reference : Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety ...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/216149
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
English
Jabbour, Serge [> >]
Seufert, Jochen [> >]
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques >]
Bailey, Clifford J. [> >]
Karup, Cathrina [> >]
Langkilde, Anna M. [> >]
2017
Diabetes, Obesity and Metabolism
Yes (verified by ORBi)
International
1462-8902
1463-1326
England
[en] SGLT2 inhibitor ; antidiabetic drug ; dapagliflozin ; type 2 diabetes
[en] AIM: To evaluate the safety and tolerability of dapagliflozin, a highly selective sodium-glucose co-transporter-2 inhibitor, in patients with type 2 diabetes mellitus (T2DM). METHODS: Data were pooled from 13 placebo-controlled trials of up to 24 weeks' duration (dapagliflozin, n = 2360; placebo, n = 2295). Larger placebo-/comparator-controlled pools of 21 (</=208 weeks; dapagliflozin, n = 5936; control, n = 3403) and 30 trials (>/=12 weeks; dapagliflozin, n = 9195; control, n = 4629) assessed the rare adverse events (AEs) of diabetic ketoacidosis (DKA) and lower limb amputation, respectively. RESULTS: Over 24 weeks, the overall incidence of AEs and serious AEs (SAEs) was similar for dapagliflozin and placebo: 60.0% vs 55.7% and 5.1% vs 5.4%, respectively. Rates of hypoglycaemia, volume depletion AEs, urinary tract infections (UTIs) and fractures were balanced between the groups. Genital infections were more frequent with dapagliflozin (5.5%) vs placebo (0.6%) and renal function AEs occurred in 3.2% vs 1.8% of patients (the most common renal AE was decreased creatinine clearance: 1.1% vs 0.7%). In the 21-study pool, 1 SAE of DKA and 3 AEs of ketonuria/metabolic acidosis occurred with dapagliflozin vs none with control; estimated combined incidence for these events was 0.03% (95% confidence interval 0.010-0.089). In the 30-study pool, lower limb amputation occurred in 8 (0.1%) and 7 (0.2%) patients receiving dapagliflozin and control, respectively. CONCLUSION: The overall incidence rates of AEs and SAEs were similar in the dapagliflozin and placebo/control groups, including the incidence of hypoglycaemia, volume depletion, fractures, UTIs, amputations and DKA. Genital infections were more frequent with dapagliflozin than placebo.
http://hdl.handle.net/2268/216149
10.1111/dom.13124
(c) 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
2017 Dapa in D2 Jabbour_et_al-2017-Diabetes,_Obesity_and_Metabolism.pdfPublisher postprint744.1 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.